-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in US stocks | Phase 1 SENTI-202 trial data positive, Senti Biosciences (SNTI.US) opened and rose more than 7%

Zhitongcaijing·12/09/2025 14:57:08
Listen to the news

The Zhitong Finance App learned that on Tuesday, Senti Biosciences (SNTI.US) opened up more than 7% to $2.54. According to the news, Senti Bio reported updated Phase 1 Senti-202 data in r/R AML, showing a 50% total remission rate (ORR), 42% complete remission/partial hematological remission (CR/CRH), and mostly minor residual negative (MRD-negative) long-lasting responses, and received RMAT support to advance to key studies.